Company intelligence / Profile preview

Nezel

Ownership: Private
Development stage: Other

Overview

Nezel is an early-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics. The company leverages its expertise in G protein-coupled receptor (GPCR) biology to target metabolic and inflammatory pathways. Nezel's current research efforts are centered on identifying high-affinity ligands for orphan receptors with the goal of addressing unmet medical needs in chronic disease management. The company is currently in the pre-clinical phase, advancing its lead candidates through lead optimization and initial safety profiling.

Therapeutic areas: ImmunologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Nezel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nezel.

Explore the full profile